

ORPHAN MEDICAL INC  
Form 8-K  
May 24, 2004

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 19, 2004

**ORPHAN MEDICAL, INC.**

(Exact name of registrant as specified in its charter)

Delaware

0-24760

41-1784594

Edgar Filing: ORPHAN MEDICAL INC - Form 8-K

(State or other jurisdiction of  
incorporation)      (Commission file number)      (I.R.S. employer identification  
number)

Suite 250,

13911 Ridgedale Drive,

Minnetonka, MN

55305

(952) 513-6900

(Address of principal executive offices)

(zip code)

(Registrant's telephone number,

including area code)

Not Applicable

(Former name or former address, if changed since last report)

---

Item 5. Other Events.

On May 19, 2004, the Company announced the initial results of a Phase III(b) clinical trial regarding its Xyrem® (sodium oxybate) oral solution product.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 19, 2004.

ORPHAN MEDICAL, INC.

/s/ Timothy G. McGrath  
Timothy G. McGrath  
Chief Financial Officer  
(duly authorized officer and  
principal financial officer)

---

EXHIBIT INDEX

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press release dated May 19, 2004.

